NICE gives Roche's MabThera final nod for non-Hodgkin's lymphoma
This article was originally published in Scrip
After another volte face NICE, the health technology appraisal institute for England and Wales has today published final guidance recommending Roche's MabThera (rituximab) as a first-line maintenance treatment for patients with follicular non-Hodgkin's lymphoma who have responded to first-line induction therapy with rituximab along with chemotherapy. Positive final draft guidance issued in May made a second U-turn on previous draft guidance (scripintelligence.com, 24 May 2011). Earlier draft recommendations put out in March said the institute could not recommend the drug without more information after looking poised to give the drug the green light in December 2010 (scripintelligence.com, 1 March 2011).
You may also be interested in...
Public health advocates say that commercial concerns must take a back seat to health interests if COVID-19 technologies are to be made available to those who need them. But industry says that relaxing IP protections is not the solution and that many companies have already invested significant amounts of money in potential new treatments and vaccines.
Recommending new medicines for approval and allowing sponsors of others extra time to answer outstanding questions are among the many tasks on the agenda of the March meeting of European Medicines Agency's key scientific committee, the CHMP. The meeting has been taking place, remotely, this week.
Intellectual property rights are under the microscope as countries prepare to provide affordable and timely access to pandemic technologies.